The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Gu,rin (BCG) immunotherapy for urothelial carcinoma of the bladder

被引：43
作者：
Rosevear, Henry M. [1 ]
Lightfoot, Andrew J. [1 ]
O'Donnell, Michael A. [1 ]
Griffith, Thomas S. [1 ]
机构：
[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
来源：
CANCER AND METASTASIS REVIEWS | 2009年 / 28卷 / 3-4期
关键词：
BCG; Neutrophil; TRAIL; Urothelial carcinoma; Bladder cancer; TUMOR-NECROSIS-FACTOR; INTRAVESICAL THERAPY; URINARY CYTOKINES; GUERIN THERAPY; CANCER STATISTICS; CRYSTAL-STRUCTURE; IN-SITU; RECEPTOR; DEATH; MECHANISM;
D O I：
10.1007/s10555-009-9195-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intravesical Mycobacterium bovis bacillus Calmette-Gu,rin (BCG) immunotherapy is a highly effective treatment for carcinoma in situ of the bladder, as well as high-risk nonmuscle invasive urothelial carcinoma of the bladder. Despite over 30 years of clinical experience with BCG, the therapy's mechanism has remained enigmatic. Observations regarding the role of neutrophils in BCG immunotherapy have led to exciting discoveries regarding the potential role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in creating the therapeutic benefit of BCG immunotherapy. In this paper, we will review the scope of the disease, highlight our understanding of the role for BCG in urothelial carcinoma of the bladder, explain the recent discoveries regarding the role of neutrophils and TRAIL in therapy, and theorize on potential future areas of research.
引用
收藏
页码：345 / 353
页数：9
相关论文
共 88 条
  • [1] BCG immunotherapy of bladder cancer: 20 years on
    Alexandroff, AB
    Jackson, AM
    O'Donnell, MA
    James, K
    [J]. LANCET, 1999, 353 (9165) : 1689 - 1694
  • [2] SUSCEPTIBILITY OF BEIGE MICE TO MYCOBACTERIUM-AVIUM - ROLE OF NEUTROPHILS
    APPELBERG, R
    CASTRO, AG
    GOMES, S
    PEDROSA, J
    SILVA, MT
    [J]. INFECTION AND IMMUNITY, 1995, 63 (09) : 3381 - 3387
  • [3] TUMOR-NECROSIS-FACTOR RECEPTOR SUPERFAMILY MEMBERS AND THEIR LIGANDS
    ARMITAGE, RJ
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (03) : 407 - 413
  • [4] EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
    Babjuk, Marko
    Oosterlinck, Willem
    Sylvester, Richard
    Kaasinen, Eero
    Boehle, Andreas
    Palou-Redorta, Juan
    [J]. EUROPEAN UROLOGY, 2008, 54 (02) : 303 - 314
  • [5] INTERNALIZATION OF BACILLE CALMETTE-GUERIN BY BLADDER-TUMOR CELLS
    BECICH, MJ
    CARROLL, S
    RATLIFF, TL
    [J]. JOURNAL OF UROLOGY, 1991, 145 (06) : 1316 - 1324
  • [6] Superficial bladder cancer:: The role of interferon-α
    Belldegrun, AS
    Franklin, JR
    O'Donnell, MA
    Gomella, LG
    Klein, E
    Neri, R
    Nseyo, UO
    Ratliff, TL
    Williams, RD
    [J]. JOURNAL OF UROLOGY, 1998, 159 (06) : 1793 - 1801
  • [7] Bhan R, 1998, Ann Diagn Pathol, V2, P55, DOI 10.1016/S1092-9134(98)80034-8
  • [8] Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer
    Bisiaux, Aurelie
    Thiounn, Nicolas
    Timsit, Marc-Olivier
    Eladaoui, Ahmed
    Chang, Huey-Hsuan
    Mapes, James
    Mogenet, Agnes
    Bresson, Jean-Louis
    Prie, Dominique
    Bechet, Stephane
    Baron, Camille
    Sadorge, Christine
    Thomas, Stephanie
    Albert, Elaine B.
    Albert, Peter S.
    Albert, Matthew L.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04) : 1571 - 1580
  • [9] Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL
    Bodmer, JL
    Meier, P
    Tschopp, J
    Schneider, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) : 20632 - 20637
  • [10] Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity
    Böhle, A
    Jocham, D
    Bock, PR
    [J]. JOURNAL OF UROLOGY, 2003, 169 (01) : 90 - 95
123456789